4.7 Article

RSPO3 impairs barrier function of human vascular endothelial monolayers and synergizes with pro-inflammatory IL-1

期刊

MOLECULAR MEDICINE
卷 24, 期 -, 页码 -

出版社

SPRINGER
DOI: 10.1186/s10020-018-0048-z

关键词

Endothelial dysfunction; RSPO3; Inflammation; Vascular leakage; IL-1 beta

资金

  1. Swiss National Science Foundation [31-124861]

向作者/读者索取更多资源

Background: Endothelial barrier dysfunction characterized by hyperpermeability of the vascular endothelium is a key factor in the pathogenesis of chronic inflammatory diseases and affects clinical outcomes. In states of chronic inflammation, mediators secreted by activated immune cells or vascular endothelium may affect the barrier function and permeability of the vascular endothelium. The matricellular R-spondin family member RSPO3 is produced by inflammatory-activated human monocytes and vascular endothelial cells, but its effects in the regulation of vascular endothelial barrier function remains elusive. Methods: The present study investigates the effects of RSPO3 on the barrier function of adult human primary macro-and micro-vascular endothelial monolayers. Tight monolayers of primary endothelial cells from human coronary and pulmonary arteries, and cardiac, brain, and dermal microvascular beds were treated with RSPO3 either alone or in combination with pro-inflammatory mediator IL-1 beta. Endothelial barrier function was assessed non-invasively in real-time using Electric Cell-substrate Impedance Sensing. Results: RSPO3 treatment critically affected barrier function by enhancing the permeability of all vascular endothelial monolayers investigated. To confer hyperpermeable phenotype in vascular endothelial monolayers, RSPO3 induced inter-endothelial gap formation by disrupting the beta-catenin and VE-cadherin alignment at adherens junctions. RSPO3 synergistically enhanced the barrier impairing properties of the pro-inflammatory mediator IL-1 beta. Conclusion: Here, we show that the matricellular protein RSPO3 is a mediator of endothelial hyperpermeability that can act in synergy with the inflammatory mediator IL-1 beta. This finding stimulates further studies to delineate the endothelial barrier impairing properties of RSPO3 and its synergistic interaction with IL-1 beta in chronic inflammatory diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

IL-4 Causes Hyperpermeability of Vascular Endothelial Cells through Wnt5A Signaling

Tom Skaria, Julia Burgener, Esther Bachli, Gabriele Schoedon

PLOS ONE (2016)

Editorial Material Immunology

Inflammatory Wnt5A signalling pathways affecting barrier function of human vascular endothelial cells

Tom Skaria, Gabriele Schoedon

JOURNAL OF INFLAMMATION-LONDON (2017)

Article Immunology

WIF1 prevents Wnt5A mediated LIMK/CFL phosphorylation and adherens junction disruption in human vascular endothelial cells

Tom Skaria, Esther Bachli, Gabriele Schoedon

JOURNAL OF INFLAMMATION-LONDON (2017)

Article Cell Biology

Oxidative Phosphorylation System in Gastric Carcinomas and Gastritis

Rene G. Feichtinger, Daniel Neureiter, Tom Skaria, Silja Wessler, Timothy L. Cover, Johannes A. Mayr, Franz A. Zimmermann, Gernot Posselt, Wolfgang Sperl, Barbara Kofler

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)

Article Pharmacology & Pharmacy

Gene Ontology Analysis for Drug Targets of the Whole Genome Transcriptome of Human Vascular Endothelial Cells in Response to Proinflammatory IL-1

Tom Skaria, Esther Bachli, Gabriele Schoedon

FRONTIERS IN PHARMACOLOGY (2019)

Article Cardiac & Cardiovascular Systems

Blood Pressure Normalization-Independent Cardioprotective Effects of Endogenous, Physical Activity-Induced αCGRP (α Calcitonin Gene-Related Peptide) in Chronically Hypertensive Mice

Tom Skaria, Katharyn Jean Mitchell, Olga Vogel, Thomas Walchli, Max Gassmann, Johannes Vogel

CIRCULATION RESEARCH (2019)

Editorial Material Biochemistry & Molecular Biology

CGRP Receptor Antagonism in COVID-19: Potential Cardiopulmonary Adverse Effects

Tom Skaria, Thomas Walchli, Johannes Vogel

Summary: The US FDA has authorized a drug repurposing trial using CGRP receptor antagonists to reduce lung inflammation in COVID-19. However, concerns about potential cardiopulmonary adverse effects of antagonizing CGRP have been raised, highlighting the importance of early detection and prevention.

TRENDS IN MOLECULAR MEDICINE (2021)

Article Pharmacology & Pharmacy

Transcriptional Regulation of Drug Metabolizing CYP Enzymes by Proinflammatory Wnt5A Signaling in Human Coronary Artery Endothelial Cells

Tom Skaria, Esther Bachli, Gabriele Schoedon

Summary: Recent research has demonstrated that the lipid-modified protein Wnt5A induces the expression of drug metabolizing enzymes CYP1A1 and CYP1B1 in human coronary artery endothelial cells, potentially affecting the metabolism of a broad spectrum of drugs including chloroquine. This finding suggests further studies are needed to explore the role of vascular endothelial cell CYP1A1 and CYP1B1 in modulating myocardial pharmacokinetics in inflammatory and cardiovascular diseases associated with Wnt5A.

FRONTIERS IN PHARMACOLOGY (2021)

Review Pharmacology & Pharmacy

Novel regulators of airway epithelial barrier function during inflammation: potential targets for drug repurposing

Ahsan Anjoom Sunil, Tom Skaria

Summary: This article reviews the endogenous factors and mechanisms that disrupt the airway epithelial barrier during inflammation, and discusses whether these factors can be specifically targeted by repurposing existing drugs.

EXPERT OPINION ON THERAPEUTIC TARGETS (2022)

Review Physiology

The Neuropeptide α-Calcitonin Gene-Related Peptide as the Mediator of Beneficial Effects of Exercise in the Cardiovascular System

Tom Skaria, Johannes Vogel

Summary: Regular physical activity has cardiovascular protective effects and increases the concentration of alpha-calcitonin gene-related peptide (alpha CGRP). Alpha CGRP plays a role in vasodilation and migraine. Mouse models suggest that loss of alpha CGRP disrupts the cardiovascular system's adaptation to exercise and worsens cardiovascular damage in chronic hypertension, which can be reversed by alpha CGRP administration. This suggests that alpha CGRP agonists may be a therapeutic option for cardiovascular protection when exercise is not possible or contraindicated. However, the long-term cardiovascular safety of anti-CGRP therapy in individuals with cardiovascular diseases is still uncertain.

FRONTIERS IN PHYSIOLOGY (2022)

Article Biology

Improved method for surgical induction of chronic hypertension in mice

Tom Skaria, Mostafa A. Aboouf, Johannes Vogel

Summary: This study presents an improved version of the 1K1C surgery in mice, which successfully induces chronic hypertension and its target organ complications without any intraoperative mortality and with excellent survival rates. The key to this method is performing unilateral nephrectomy one week after renal artery clipping to slow down the increase in blood pressure.

BIOLOGY OPEN (2022)

Meeting Abstract Cardiac & Cardiovascular Systems

Vasodilation- and blood pressure normalization-independent cardioprotective effects of endogenous, physical activity-induced alpha calcitonin gene-related peptide in chronic hypertension

T. Skaria, K. Mitchell, J. A. Fischer, W. Born, M. Gassmann, J. Vogel

EUROPEAN HEART JOURNAL (2019)

暂无数据